Last CNY23.44 CNY
Change Today +0.37 / 1.60%
Volume 987.6K
002644 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 3:00 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

lanzhou foci pharmaceutica-a (002644) Snapshot

Open
CNY23.05
Previous Close
CNY23.07
Day High
CNY23.58
Day Low
CNY22.81
52 Week High
10/10/14 - CNY26.65
52 Week Low
10/29/13 - CNY10.85
Market Cap
4.2B
Average Volume 10 Days
2.3M
EPS TTM
CNY0.17
Shares Outstanding
177.7M
EX-Date
05/21/14
P/E TM
137.9x
Dividend
CNY0.02
Dividend Yield
0.07%
Current Stock Chart for LANZHOU FOCI PHARMACEUTICA-A (002644)

Related News

No related news articles were found.

lanzhou foci pharmaceutica-a (002644) Related Businessweek News

No Related Businessweek News Found

lanzhou foci pharmaceutica-a (002644) Details

Lanzhou Foci Pharmaceutical Co., Ltd. manufacturers and distributes traditional Chinese medicines primarily in China. The company offers its products in the forms of pills, tablets, capsules, granules, etc. under the Min Shan and Foci brand names. Lanzhou Foci Pharmaceutical Co., Ltd. also exports its products to approximately 27 countries and areas, such as the United States, the United Kingdom, Canada, Japan, Singapore, Indonesia, Thailand, Malaysia, the Netherlands, New Zealand, Australia, Russia, Ukraine, and Hong Kong. The company was founded in 1929 and is based in Lanzhou, China.

Founded in 1929

lanzhou foci pharmaceutica-a (002644) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

lanzhou foci pharmaceutica-a (002644) Key Developments

Lanzhou Foci Pharmaceutical Co.,Ltd. Approves Amendments to Articles of Association

Lanzhou Foci Pharmaceutical Co.,Ltd. held its second extraordinary general meeting of 2014 on 13 October 2014, during which the shareholders of the company approved amendments to the company's articles of association.

Lanzhou Foci Pharmaceutical Co.,Ltd. Proposes Amendments to Articles of Association

Lanzhou Foci Pharmaceutical Co.,Ltd. proposed amendments to the company's articles of association at its second Extraordinary General Meeting of 2014 to be held on October 13, 2014.

Lanzhou Foci Pharmaceutical Co.,Ltd., Special/Extraordinary Shareholders Meeting, Oct 13, 2014

Lanzhou Foci Pharmaceutical Co.,Ltd., Special/Extraordinary Shareholders Meeting, Oct 13, 2014., at 14:00 China Standard Time. Agenda: To consider amendments to the company's articles of association; to consider formulation of the plan for the shareholders profit return for the next three years; to consider amendments to the company's rules of procedures governing shareholders' general meetings; to consider amendments to the raised fund management system; to consider adjustment to the valid period of the resolution on scheme for non-public share offering to specific parties; and to consider adjustment to the valid period of authorization to the board to handle matters in relation to non-public share offering.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002644:CH CNY23.44 CNY +0.37

002644 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002644.
View Industry Companies
 

Industry Analysis

002644

Industry Average

Valuation 002644 Industry Range
Price/Earnings 100.0x
Price/Sales 11.8x
Price/Book 5.9x
Price/Cash Flow 128.3x
TEV/Sales 10.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LANZHOU FOCI PHARMACEUTICA-A, please visit www.fczy.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.